RBC Capital Maintains Sector Perform on Intercept Pharma, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains Intercept Pharma (NASDAQ:ICPT) with a Sector Perform and raises the price target from $12 to $19.
September 27, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intercept Pharma's price target has been raised from $12 to $19 by RBC Capital, which maintains the company with a Sector Perform.
The news of RBC Capital raising the price target for Intercept Pharma from $12 to $19 while maintaining a Sector Perform rating is likely to have a positive impact on the company's stock in the short term. This is because it signals the analyst's increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100